IMMUNOTHERAPY

DOWNLOAD AGENDA

Immunotherapy, Tuesday 19 March 2019

08:45

Organiser’s welcome Remarks

Joe Zhou
08:50

Chair’s opening Remarks

Joe Zhou, Chief Executive Officer, Genor BioPharma, Walvax Group

Opening Keynote Plenary

David Lane
09:00

Going global and keeping it local: Is biotech innovation sustainable in Asia?

In this keynote presentation, Sir David Lane, one of the key scientists credited on the discovery of cancer gene p53, a gene which mutation cause near 50% of all human cancer, will share his view on how biomedical sciences have developed in Singapore, Japan and the remaining APAC region, and prospects for Asian biotech and pharma industry.
Byung-Geon Rhee
09:20

Looking east: Integrating Asia into the global era of innovative medicine

Panel discussion
09:40

Pharma Trends: Women health as the next focus

Women’s health goes beyond mother & childcare. For instance, women has a higher risk of cardiovascular diseases compared to men, hence there is a need to invest more on addressing the biological differences in mainstream disease studies to ensure a more effective, personalised treatment. In addition, big data & AI application on female subjects may also differ from male subjects, prompting a need to investigate how studies should be developed differently in the future. This panel brings experts to debate and discuss how femtech is shaping to be the next global pharma focus and the new areas of focus in women's healthcare.
10:20

Exhibition visit & networking refreshments

GOING GLOBAL AND KEEPING IT LOCAL

Frank Jiang
Immunotherapy
11:15

Chair's opening remarks

Aung Myo
Immunotherapy
11:20

What’s next after PD-L1?

Jeonghoon Han
Immunotherapy
11:40

How do domestic companies gain edge in the competitive global immunotherapy landscape?

Frank Jiang
Immunotherapy
12:00

The next big trend in Asia immunotherapy landscape: A case study in China

Antonio Lee
Immunotherapy
12:20

Development of cell therapy product for pediatric orphan disease - challenges and rewards

  • Case study on current and upcoming immunotherapy and stem cell products, i.e. Cartistem, Pneumostem (orphan indication for premature babies)
  • Discussion on strategies in making immunotherapy and stem cell products more accessible for population in Asia, future plans and what’s next beyond Asia?
12:40

Exhibition Visit & Networking Lunch

IMMUNO-ONCOLOGY (I-O) IN ASIA

Josemund Menezes
Immunotherapy
14:10

Chair’s opening remarks

Stefan Glück
Immunotherapy
14:20

Big pharma perspectives: Using global pipeline development to serve Asia’s population

Mai Jing Liao
Immunotherapy
14:40

Innovative therapeutics in immuno-oncology and inflammatory diseases

Mahboob Rahman
Immunotherapy
15:00

Glenmark Pharmaceuticals Product Launch

Piers Ingram
Immunotherapy
15:20

Immunotherapy in clinical practices: Opportunities and key challenges (Topic to be confirmed)

15:40

Exhibition Visit & Networking Refreshments

CANCER VACCINES

Dwo Yuan Sia
Immunotherapy
16:40

Beyond prevention: Latest cancer vaccine developments in Asia

Nick Ede
Immunotherapy
17:00

Gastric and breast cancer vaccines: Case study and latest findings

Immunotherapy
17:20

Next Generation Therapeutic Cancer Vaccines Affordable to the Masses

17:40

Networking Cocktail & End of Conference Day 1

last published: 19/Feb/19 03:35

Immunotherapy, Wednesday 20 March 2019

08:45

Organiser’s welcome Remarks

08:50

Chairman’s opening Remarks

Nadia Suttikulpanich
09:00

Disrupt before being disrupted: Using digital tech to connect to previously uneconomic chronic disease customers

Insurance is a tricky part of healthcare business. Increased healthcare costs lead to a higher profit for pharma and provider companies but burdens the government budget and hurts the insurance business. Since taking care of a chronic patient is a lifelong commitment, the availability of insurance to cover this essential treatment is often expensive and uneconomical. Join Nadia Suttikulpanich, Head of the Fuchsia Innovation Center, part of Muang Thai Life Assurance, Thailand as she shares how they are adopting digital tech to pilot chronic disease cover to provide for patients in need while keeping their insurance business profitable.
Edward Rosen
09:20

The path to personalised medicine: Key developments

Everyone knows the potential benefits of personalised medicine, but how do we get there? Finding and better defining disease through biomarkers and more accurate diagnostics. Targeted therapeutics to leverage new and emerging diagnostic capabilities. Personalized Medicine to Real-Time Medicine. How to drive success across industry and clinical implementation in an economic manner. This presentation discusses various strategies and key considerations to drive the symbiosis between academia, industry and clinical medicine to drive vastly improved patient outcomes.
10:20

Roundtable discussion

Table 1 Working with clinical outsourcing partners: Risk management and prevention

Table 2 Fostering commercial partnerships to tap on emerging APAC markets

Table 3 Regulatory collaboration and opportunities in more efficient drug development

Table 4 Strategies in making drugs more affordable and accessible to patients in developing countries

Table 5 Universal healthcare- Is it really costly?

Table 6 A convergent approach: Tapping on western expertise to serve Asia population

Table 7 Precision to personalised medicine- How do we get there?

Table 8 Leveraging blockchain technology in making clinical trials more transparent and efficient

Table 9: Data Science in practice: How can sales reps and MSLs use Big Data?

Prabhuram Krishnan, South Asia Medical Director, Ipsen Pharma

Table 10: The Singapore biotech ecosystem – What comes after the Inflexion?

11:00

Exhibition Visit & Networking Refreshments

TARGETTED THERAPIES

Panel discussion
Immunotherapy
11:40

Overview: Targeted therapies in enabling precision medicine

  • Combination studies in Asia-latest updates
  • Deciding between targeted oncology therapies vs I-O, key considerations
  • Key actions transitioning from followers to leaders in targeted therapies
Wenzhi Tian
Immunotherapy
12:20

Development of next generation tumor immunotherapy

Vivian Bian
Immunotherapy
12:40

Next generation targeted agents and immuno-oncology therapies

13:00

Exhibition Visit & Networking Lunch

COMBINATION AND NOVEL THERAPIES

George Kopsidas
Immunotherapy
14:30

When two readily becomes one: Opportunities in bispecific antibodies

Gang Qin
Immunotherapy
14:50

Next generation combination therapies with bioconjugation

Immunotherapy
15:10

Device-Drug combination: The next generation combination therapy

IMMUNOTHERAPY BEYOND ONCOLOGY

Immunotherapy
15:50

Immunotherapy in treating autoimmune and degenerative diseases

Alexander Kort
Immunotherapy
16:10

Applying precision and immunotherapy to prevent infectious diseases

16:30

End of Phar-East 2019

last published: 19/Feb/19 03:35

 

 

DOWNLOAD PROSPECTUS

 

 

For speaking, sponsorship and exhibition opportunities contact jonathan.mottram@terrapinn.com
Tel: +65 6322 2738